Clinical Trial Update: Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a combination of elotuzumab, iberdomide, and dexamethasone after idecabtagene vicleucel (ide-cel) in patients with rela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• iberdomide (iberdomide)

Snippet

Sponsor: Omar Nadeem, MD | Conditions: Myeloma, Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING